Ticker

MRK

Merck & Co., Inc.

5 catalysts on file

MRK

Merck & Co., Inc.

Approval AI-extracted

IDVYNSO

HIV-1

113d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

MRK

Merck & Co., Inc.

Phase 3 AI-extracted

Undisclosed program

113d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

MRK

Merck Sharp & Dohme LLC

Phase 3 Estimated

Belzutifan

Carcinoma, Renal Cell

T-minus 68 days Oct 28, 2026

ClinicalTrials.gov verified 2mo ago

Countdown card →

MRK

Merck Sharp & Dohme LLC

Phase 2 Estimated

Tulisokibart

Hidradenitis Suppurativa

T-minus 87 days Nov 16, 2026

ClinicalTrials.gov verified 2mo ago

Countdown card →

MRK

Merck Sharp & Dohme LLC

Phase 2 Estimated

Coformulated favezelimab/pembrolizumab

Metastatic Urothelial Carcinoma

T-minus 283 days May 31, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →